Showing 1101-1110 of 9757 results for "".
New Products and Therapeutic Focus: Lasers
https://practicaldermatology.com/columns/new-products/new-products-and-therapeutic-focus-lasers/21089/The Hidradenitis Suppurativa Therapeutic Pipeline
https://practicaldermatology.com/topics/rare-disease/the-hidradenitis-suppurativa-therapeutic-pipeline/54824/Though treatment options are currently limited, the pipeline for HS therapeutics is active with numerous medications in development.Update on Injectable Aesthetics
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/update-on-injectable-aesthetics/23467/Medical Derm at Summer AAD; Novel Drugs, Acne at Derm 2018
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-medical-derm-at-summer-aad-novel-drugs-acne-at-derm-2018/18244/The Summer meeting of the American Academy of Dermatology (AAD) gathers members for updates on medical and aesthetic advancements. This year, topics included advanced therapeutics, skin cancer, and skin of color. DERM 2018 provides an opportunity for nurse practitioners and physician assistants in dAssessing the Aging Face
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/assessing-the-aging-face/18849/Jason Emer, MD discusses the evolving filler market and new trends in facial rejuvenation treatments. He offers tips for assessing patients globally—in three and four dimensions—in order to choose the right options for contouring the face with fillers and fat in order to give patients the most naturDermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approveDermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent eDermWireTV: Cassiopeia Winlevi; Psoriasis Guidelines; Cyndi Lauper's PsO in the Know; Sarah Michelle Gellar's CoolSculpting
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cassiopeia-winlevi-psoriasis-guidelines-cyndi-laupers-pso-in-the-know-sarah-michelle-gellars-coolsculpting/19852/The FDA has approved Winlevi (Clascoterone cream 1%) from Cassiopea for the treatment of acne in patients 12 years and older.New Guidelines of care for the Management of Psoriasis with Systemic Nonbiologic Therapies, jointly issued by the American Academy of Dermatology and the National Psoriasis FoJanssen Approvals, New Thermage FLX, Restylane Silk Cannulas
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-janssen-approvals-new-thermage-flx-restylane-silk-cannulas/18401/Janssen Biotech's Stelara is now approved for the treatment of adolescents 12 years of age or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Janssen's SIMPONI ARIA® cleared for the treatment of adults with active psoriatic arthritis or activeSummer AAD Highlights, Alopecia Areata Discovery
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-summer-aad-highlights-alopecia-areata-discovery/18846/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, new research that suggests emerging biologic therapies could help treat alopecia areata. Plus, updates on atopic dermatitis and eczema, hands-on education, and Kybella from the AAD Summer meeting. And